anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
A semi conductor material, e.g. silicon, germanium, silicon carbide or an AIIIBV compound, is deposited epitaxially from the gas phase, e.g. a halide, on a monocrystalline semi-conductor wafer by placing said wafer in a recess in a horizontal support member and heating said support member by passing an electric current through it.  A supplementary heating member located beneath, but not touching the support member, supplies to said support member an amount of heat equal to that lost by radiation from the underside of said support member.  The various parts of the apparatus may be coated with SiO2, to prevent the deposition of impurities.ALSO:A semi-conductor material, e.g. silicon, germanium, silicon carbide or an AIIIBV compound, is deposited epitaxially from the gas phase, e.g. a halide, on a monocrystalline semiconductor wafer by placing said wafer in a recess in a horizontal support member and heating said support member by passing an electric current through it.  A supplementary heating member located beneath, but not touching the support member, supplies to said support member an amount of heat equal to that lost by radiation from the underside of said support member. The various parts of the apparatus may be coated with SiO2 to prevent impurities from being deposited.
Iron deficiency (ID) is common in patients with acute myocardial infarction (AMI). It is unknown whether patients with AMI combined with ID will benefit from iron supplementation therapy. This study aimed to assess the relationship between iron therapy and mortality in AMI patients. Retrospective analysis was performed in subjects screened from the Medical Information Mart in Intensive Care-IV database. The data were obtained from ICU patients admitted to Beth Israel Deaconess Medical Center between 2008 and 2019. The patients were divided into two groups according to iron treatment exposure. Propensity score matching (PSM) was performed in the original cohort at a 1:1 ratio. Univariate and multivariate analyses were performed to adjust for confounding factors. The primary outcome was 28-day mortality. A total of 426 patients were included in this study. After 1:1 PSM, 208 patients were analyzed. Iron treatment was associated with a lower risk of 28-day mortality (9 deaths (8.65%) in the iron treatment group vs. 21 deaths (20.19%) in the non-iron treatment group; HR = 0.39; 95% CI = 0.17-0.89; p = 0.025) and in-hospital mortality (4 deaths (3.85%) in the iron treatment group vs. 12 deaths (11.54%) in the non-iron treatment group; OR, 0.15; 95% CI, 0.03-0.74; p = 0.029). Iron treatment was associated with reduced 28-day mortality in patients with AMI combined with ID. Iron treatment had no significant effect on the length of hospitalization or the length of ICU stay. Prospective studies are needed to verify this conclusion.
This review article describes the methods and clinical recommendations for reinforcing traumatized anterior immature teeth with pulp necrosis treated with mineral trioxide aggregate (MTA) apexification. Traumatic injury can cause pulp necrosis and incomplete root formation in immature teeth. MTA apexification is the treatment of choice for necrotic immature teeth, particularly during the middle or late stages of root development. MTA apexification has a high success rate; however, failures due to cervical or root fractures occasionally occur. The risk of fracture is higher in immature teeth with thin root dentin, particularly those with external root resorption. Furthermore, the loading force from any parafunctional habit also increases fracture risk. Therefore, intra-radicular reinforcement may be necessary after MTA apexification. In vitro, intraradicular restoration with a resin composite/core build-up material or a prefabricated fiber post demonstrated better root reinforcement than root canal obturation materials (i.e., gutta-percha and sealer). However, the root-reinforcement effect of MTA orthograde filling in the entire root canal remains unclear. In vivo, the survival of fractured teeth with intraradicular restorations (resin composite/core build-up material or prefabricated fiber posts) is extremely high. Moreover, the survival of teeth with gutta-percha/sealer obturation or MTA orthograde filling and restoration with resin composite extending into the cervical third of the root canal approximately 1-2 mm below the cemento-enamel junction is acceptably high. Based on this evidence, the remaining tooth/root structure and loading force should be carefully examined when considering intra-radicular reinforcement of immature anterior teeth treated with MTA apexification.
FIELD: medicine.SUBSTANCE: patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/mand exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/mand time of exposure of 20 seconds per each 1 cmof the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days.EFFECT: safe and effective conservative treatment of the intestinal fistulas at any phase of the wound process that enables avoiding risks of surgical intervention and general anaesthesia by rapid reduction of skin maceration and perifocal inflammation surrounding the mouth and prevents them, stimulates the growths of granulocyte tissue and epithelisation of the fistuous wound.
Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as ciprofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing ciprofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential adverse reaction and advised to discontinue ciprofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur. [See Boxed Warning, Warnings and Precautions (5.1), and Adverse Reactions (6.2).] 

  


In a retrospective analysis of 23 multiple-dose controlled clinical trials of ciprofloxacin encompassing over 3500 ciprofloxacin-treated patients, 25% of patients were greater than or equal to 65 years of age and 10% were greater than or equal to 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals on any drug therapy cannot be ruled out. Ciprofloxacin is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. No alteration of dosage is necessary for patients greater than 65 years of age with normal renal function. However, since some older individuals experience reduced renal function by virtue of their advanced age, care should be taken in dose selection for elderly patients, and renal function monitoring may be useful in these patients. [See Dosage and Administration (2.3) and Clinical Pharmacology (12.3).]

In general, elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using ciprofloxacin with concomitant drugs that can result in prolongation of the QT interval (for example, class IA or class III antiarrhythmics) or in patients with risk factors for torsade de pointes (for example, known QT prolongation, uncorrected hypokalemia). [See Warnings and Precautions (5.10).]
Methylphenidate Hydrochloride oral solution is a mild central nervous system (CNS) stimulant available as 5 mg/5 mL and 10 mg/5 mL oral solutions for oral administration. Methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is

Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone.

Each mL of Methylphenidate Hydrochloride Oral Solution 5 mg/5 mL contains 1 mg of methylphenidate hydrochloride USP.

Each mL of Methylphenidate Hydrochloride Oral Solution 10 mg/5 mL contains 2 mg of methylphenidate hydrochloride USP.

In addition, Methylphenidate Hydrochloride Oral Solution also contains the following inactive ingredients: artificial grape flavor, glycerin, hydrochloric acid, maltitol syrup, propylene glycol, purified water, sodium hydroxide, and sorbitol. Hydrochloric acid may be added to adjust pH.
At present, the novel cheap and effective intervention against menopause related symptoms such as memory impairment and osteoporosis is still required due to the increased breast cancer risk induced by hormone replacement therapy. Based on the role of oxidative stress on cognitive deficit in menopause and the synergistic effect of herbs in traditional folklore, the cognitive enhancing effects and anti-osteoporosis effects of the functional food containing the combined extract of herbs possessing antioxidant effect has gained attention. Therefore, we aimed to determine the effect of the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) on cognitive function and bone formation markers of menopausal women. Forty-five participants were randomly assigned to receive a placebo or MP (50, 1500 mg) treatments once daily for 8 weeks. The cognitive function and working memory were assessed via the auditory oddball paradigm of event-related potentials and computerized battery tests respectively prior to the intervention, 1 month, 2 month, and at delay 1 month. Bone formation markers including serum calcium, alkaline phosphatase, and osteocalcin were determine prior to the intervention and at the end of study.
The primary goal of this study is to examine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder (BD II). Fourteen participants, ages 18 to 70 with clinically diagnosed BD II with active depression, in active outpatient mental health treatment, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by an initial drug administration of oral psilocybin,supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will complete assessment and integration sessions with the facilitators subsequently in order to help process the experience. Participants who tolerated the first dosage may be asked to complete a second psilocybin dosing session, involving the same preparation, procedures, integration, and supervision as the first. Primary outcome measures will assess safety, tolerability, and feasibility of study procedures. Efficacy will be measured by change in depression as measured by the MADRS three weeks after the final psilocybin administration. Exploratory outcome measures will assess changes in sleep, quality of life, and therapeutic engagement.
This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
A phospholipase A2 inhibitor protein designated 'Phospholipase inhibitor from Python' (PIP), formerly designated 'Python Antitoxic Factor' (PAF), the partial amino acid sequence for which was initially determined from the native protein purified from the blood serum of a nonvenomous snake, Python reticulatus, and given by SEQ ID NO:1. The complete PAF polynucleotide sequence was obtained from a cDNA clone encoding PIP (or PAF), and given by SEQ ID NO:2 along with the full amino acid sequence deduced from it. Also a recombinant protein PIP (or PAF) which shows strong lethal toxin neutralizing activity similar to the native PIP (or PAF), and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP (or PAF) are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, a potent phospholipase A2 (PLA2) inhibitory polypeptide designated P-0029 (SEQ ID NO:10), and moderately active PLA2-inhibitory polypeptides, P-0009 and P-0006, the sequences of which are given as SEQ ID NO:11 and SEQ ID NO:12, respectively. Those polypeptides, and their synthetic chemical analogues, or polypeptide variants that inhibit PLA2 activity and alleviate inflammation, may also be used in the diagnosis, study, prevention, and treatment of PLA2-related human inflammatory diseases.
INTRODUCTION/AIMS: Nerve enlargement has been described in autoimmune nodopathy and chronic inflammatory demyelinating polyneuropathy (CIDP). However, comparisons of the distribution of enlargement between autoimmune nodopathy and CIDP have not been well characterized. To fill this gap, we explored differences in the ultrasonographic and electrophysiological features between autoimmune nodopathy and CIDP.
METHODS: Between March 2015 and June 2023, patients fulfilling diagnostic criteria for CIDP were enrolled; among them, those with positive antibodies against nodal-paranodal cell-adhesion molecules were distinguished as autoimmune nodopathy. Nerve ultrasound and nerve conduction studies (NCS) were performed.
RESULTS: Overall, 114 CIDP patients and 13 patients with autoimmune nodopathy were recruited. Cross-sectional areas (CSA) at all sites were larger in patients with CIDP and autoimmune nodopathy than in healthy controls. CSAs at the roots and trunks of the brachial plexus were significantly larger in patients with anti-neurofascin-155 (NF155), anti-contactin-1 (CNTN1), and anti-contactin-associated protein 1 (CASPR1) antibodies than in CIDP patients. The patients with anti-NF186 antibody did not have enlargement in the brachial plexus. NCS showed more frequent probable conduction block at Erb's point in autoimmune nodopathy than in CIDP (61.9% vs. 36.6% for median nerve, 52.4% vs. 39.5% for ulnar nerve). Markedly prolonged distal motor latencies were also present in autoimmune nodopathy.
DISCUSSION: Patients with autoimmune nodopathies had distinct distributions of peripheral nerve enlargement revealed by ultrasound, as well as distinct NCS patterns, which were different from CIDP. This suggests the potential utility of nerve ultrasound and NCS to supplement clinical characteristics for distinguishing nodopathies from CIDP.
Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care for heart failure management without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 13 months.
The present disclosure relates generally to user interfaces for health applications. In some embodiments, an exemplary user interface for managing health and security features on an electronic device is described. In some embodiments, an example user interface for managing settings of health features on an electronic device is described. In some embodiments, an example user interface for managing background health measurements on an electronic device is described. In some embodiments, an example user interface for managing biometric measurements made using an electronic device is described. In some embodiments, an example user interface for providing results of captured health information on an electronic device is described. In some embodiments, an example user interface for managing background health measurements on an electronic device is described.
[PROBLEMS] To provide a functional nucleic acid bound to a nucleic acid homopolymer which can impart a stability-improving effect to a physiologically active nucleic acid in a simple manner and a process for production of the functional nucleic acid. [MEANS FOR SOLVING PROBLEMS] Disclosed is a process for production of a functional nucleic acid bound to a nucleic acid homopolymer which comprises a functional nucleic acid and a nucleic acid homopolymer and can be used as a stabilized functional nucleic acid. The process comprises adding the nucleic acid homopolymer to the functional nucleic acid to yield a nucleic acid homopolymer-bound functional nucleic acid. The nucleic acid homopolymer is preferably a homopolymer of deoxyaqdenylic acid and/or a homopolymer of deoxythymidylic acid. The nucleic acid homopolymer has a length of about 3- to 50-mer, for example. Examples of the functional nucleic acid include siRNA, antisense, miRNA, an aptamer and the like.
BACKGROUND: Digital Polymerase Chain Reaction (dPCR) presents a promising approach for quantifying DNA and analyzing copy number variants, particularly in non-invasive prenatal testing. This method offers a streamlined and time-efficient procedure in contrast to the widely used next-generation sequencing for non-invasive prenatal testing. Studies have reported encouraging results for dPCR in detecting fetal autosomal aneuploidies. Consequently, this systematic review aimed to evaluate the effectiveness of dPCR in screening for trisomy 21, 18, and 13.
METHODS: A systematic search was conducted in PubMed, Web of Sciences, and Embase for relevant articles published up to December 30, 2023. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was utilized for the quality assessment of the included articles. Furthermore, a bivariate random-effect regression model was used to conduct a meta-analysis on the utility of dPCR for trisomy 21 screening.
RESULTS: A total of 9 articles were included in this review, with all of them assessing the utility of dPCR in trisomy 21 screening, and 2 and 1 studies conducting additional analysis on the screening abilities of dPCR for trisomy 18 and 13, respectively. A bivariate random-effects model calculated pooled sensitivity and specificity with a 95% confidence interval (CI). Meta-analysis of 6 studies comparing trisomy-21 screening with karyotyping demonstrated dPCR's pooled sensitivity of 98% [95% CI: 94 -100] and specificity of 99% [95% CI: 99 -100]. While conducting a meta-analysis for trisomy 13 and 18 proved impractical, reported values for sensitivity and specificity were favorable.
CONCLUSIONS: These findings suggest that dPCR holds promise as an effective tool for non-invasive prenatal testing, presenting a less time-consuming and intricate alternative to next-generation sequencing. However, further research is necessary to evaluate dPCR's applicability in clinical settings and to delineate its specific advantages over next-generation sequencing. This study contributes valuable insights into the potential of dPCR for enhancing prenatal screening methodologies.
TRIAL REGISTRATION: The protocol of this study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) on 7/3/2024, with a registration code of CRD42024517523.
This invention describes the synthesis and study of a new morpholine derivative with antioxidant, hypocholesterolaemic and hypolipaemic action. The new morpholine derivative is 2-hydroxy-2-diphenyl-5,6- tetramethylene-4-methyl morpholine hydrochloride 1 which is synthesised from 2-bromo-4-phenyl-acetophenone and 2- methylaminocyclohexanol. Formula 1. The new compound lowers total plasma cholesterol levels by 54%, total plasma triglyceride levels by 49% and plasma LDL- cholesterol levels by 51%. The new compound has powerful antioxidant properties. Offering such properties, the new compound should be capable of effective use in treating hypercholesterolaemia, hyperlipidaemia and arteriosclerosis.
One-hundred FPMs with MIH which were indicated for non-invasive fissure sealant were selected in 39 children (between 6-12 years). Using a split mouth design, the FPMs were randomized into two groups; Group 1: resin sealant (Conceal F); Group 2: giomer sealant (BeautiSealant) and dental isolation device was used during the procedure (Mr. Thursty). Clinical evaluation was performed by two blinded examiners using the United States Public Health Service (USPHS) criteria to assess anatomical form, marginal adaptation, surface texture, marginal discoloration, retention and secondary caries at 1, 3, 6 and 12 months. Statistical analysis was performed using SPSS 20.0 software (IBM Corp., Chicago, IL, USA) and the level of significance was set at p\<0.05. The association between independent variable (groups) and dependent variable (USPHS scores) was evaluated with Fisher's exact test. The crosstabulation of the categorical data regarding the groups were analyzed with chi-square test or Fisher's exact test. The Log-rank test and Kaplan-Meier analysis were used to calculate and compare the cumulative survival rates of the sealants.